Crinetics Pharmaceuticals CRNX 深 沪
等待开盘 09-03 09:30:00 美东时间
33.30
+2.310
+7.45%
华盛通- 最 高33.44
- 今 开31.09
- 成交量 146.54万股
- 最 低 31.00
- 昨 收 30.99
- 总市值 31.36亿
- 52周最高 62.53
- 市盈率 静 --
- 换手率 1.56%
- 52周最低 24.10
- 委 比 -68.67%
- 总股本 9417.60万
- 历史最高 62.53
- 量 比 1.79
- 振 幅 7.87%
- 历史最低 10.63
- 每 手 1
- 风险率 11.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
Crinetics Pharmaceuticals announced that the FDA granted Orphan Drug Designation (ODD) for atumelnant, a novel once-daily oral ACTH receptor antagonist for treating classic congenital adrenal hyperplasia (CAH). Atumelnant is the first small molecule ACTH receptor antagonist in clinical development. The company highlighted the significant unmet need for CAH patients and aims to demonstrate the ability to restore normal adrenal androgen levels and ...
08-21 12:45
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reported Q2 2025 financial results, highlighting progress toward its acromegaly drug PALSONIFY™ with an FDA PDUFA date of Sept 25, 2025. The company advanced multiple clinical programs, including atumelnant for CAH, and presented data at major medical meetings. Cash reserves of $1.2B are expected to support operations into 2029.
08-07 20:05
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
Data from Crinetics' clinical trials show that PALSONIFY (paltusotine), an oral treatment for acromegaly, demonstrated durable control of IGF-1 levels, reduced symptom burden, and was well-tolerated during long-term use. Results from the PATHFNDR-1 and PATHFNDR-2 open-label extensions, presented at ENDO 2025, highlight PALSONIFY's potential as a next-generation therapy for acromegaly. In PATHFNDR-1, 91% of participants transitioned to the open-...
07-13 21:45
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
<p>Cisinetics Pharmaceuticals announced it will report its second quarter 2025 financial results on August 7, 2025 after market close. The company will host a conference call at 4:30 p.m. ET to discuss the results and provide a business update. Participants can join via phone using domestic number 1 833-470-1428 or international number 1 404-975-4839 with access code 899803. The call will also be webcast live and archived on the company's website...
07-11 12:00
Crinetics Pharmaceuticals Presents at ENDO 2025 Meeting
The latest announcement is out from Crinetics Pharmaceuticals ( ($CRNX) ). On J...
07-01 04:52
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
<p>San Diego, June 30, 2025. Crinetics Pharmaceuticals announced eight abstracts from its novel clinical programs, including PALSONIFY™ (paltusotine) and atumelnant, will be presented at ENDO 2025 in San Francisco. PALSONIFY continues to show long-term efficacy and safety in acromegaly patients, whether switching treatments or newly untreated. Atumelnant’s Phase 2 results in congenital adrenal hyperplasia (CAH) will be highlighted, along with upd...
06-30 20:05
美股大行评级 | 潜在涨幅205.56%！康托·菲茨杰拉德上调HIVE Digital Technologies目标价至5.5美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1145638202455883776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 康托·菲茨杰拉德：维持HIVE Digital Technologies(HIVE)"超配"评级，目标价从5美元升至5.5美元</p> <p>• BTIG：维持Theravance Biopharma(TBPH)"买入"评
06-28 08:37
HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $81 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy and maintains $81 price target.
06-27 19:13
Crinetics Pharmaceuticals Unveils Promising Preclinical Pipeline
Crinetics Pharmaceuticals ( ($CRNX) ) just unveiled an announcement. On June 26...
06-27 04:48
